ALK and non-small cell lung carcinoma: ,2 For ICIs, that is, agents targeting programmed cell death protein-1 or programmed death-ligand 1 (PD-L1), either as monotherapy or in combination with chemotherapy, a therapeutic benefit has been established in NSCLC populations that typically exclude patients with EGFR or ALK mutations.12